1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

12 Oct 2022
Admin
News Article

Wuxi Biologics And Toregem Biopharma Sign Mou For Development Of Anti-Usag-1 Antibody

Wuxi Biologics, A Leading Global Contract Research, Development And Manufacturing Organization (Crdmo), And Toregem Biopharma, A Biotech Startup Company From Kyoto University, Today Announced That They Have Signed A Memorandum Of Understanding (Mou) To Form A Strategic Partnership In The Development Of Trg035, A Monoclonal Antibody Targeting Usag-1 For The Treatment Of Congenital Adentia.Within The Partnership, Toregem Biopharma Will Have Access To Wuxi Biologics' Integrated Cmc Services In Cell Line Development, Cell Banking And Testing Services, Cell Culture Development, Biologics Gmp Manufacturing, Bioassay Development, And Related Services. Wuxi Biologics Will Support Toregem Biopharma On The Trg035 Project For Its Investigational New Drug (Ind) Application."We Are Glad To Be Collaborating With Wuxi Biologics As They Are Experienced In Enabling Universities To Turn Advanced Technologies Into Promising Products," Said Dr. Honoka Kiso, Ceo Of Toregem Biopharma. "By Utilizing Wuxi Biologics' Comprehensive Ind-Enabling Capabilities And Large Global Footprint With Extensive Gmp Production Capacities, Toregem Biopharma Will Be Able To Focus On Realizing And Maximizing The Therapeutic Potential Of Trg035. Wuxi Biologics Is The Best Partner For Us As We Step Forward To Conduct The Clinical Trial And Realize The Eventual Commercialization Of Our Unique Product. We Look Forward To Bringing This Tooth Regeneration Drug To The Global Market, Treating Patients Across The World."Dr. Chris Chen, Ceo Of Wuxi Biologics, Commented, "We Are Very Pleased To Partner With Toregem Biopharma, And This Is One Of The First Integrated Cmc Projects In Japan That We Have Supported

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!